In VivoThree years after In Vivo identified AI in biologics as “an emerging frontier,” pharmaceutical companies are doubling down with billion-dollar partnerships and comprehensive internal platforms. Ye
Pink SheetThe consumer representative for the US Food and Drug Administration’s Pediatric Advisory Committee said the adverse event reporting system needs improvement and the agency’s postmarketing surveillance
ScripFrontline Indian firms appear keen to accelerate product in-licensing deals with foreign companies and these efforts have now evolved from a “supplementary tactic” to a cornerstone of their strategy,
ScripThe recent removal of the Risk Evaluation and Mitigation Strategies (REMS) requirement for approved cellular CAR-T therapies for cancer was lauded as an expansion of the market from the two-in-10 el